Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA FeedbackGlobeNewsWire • Tuesday
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 05/02/24
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash PositionGlobeNewsWire • 04/30/24
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™GlobeNewsWire • 04/15/24
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionGlobeNewsWire • 04/04/24
Invivyd Reports Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/28/24
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical TrialGlobeNewsWire • 03/22/24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19GlobeNewsWire • 03/22/24
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 02/05/24
All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong BuyZacks Investment Research • 01/12/24
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19GlobeNewsWire • 12/18/23
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/09/23
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 11/02/23
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19GlobeNewsWire • 09/11/23
Invivyd Reports Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/10/23
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/03/23